Cellosaurus logo
expasy logo

Cellosaurus WM39 (CVCL_2240)

[Text version]
Cell line name WM39
Synonyms WM-39; WM 39; WC00077
Accession CVCL_2240
Resource Identification Initiative To cite this cell line use: WM39 (RRID:CVCL_2240)
Comments Part of: Wistar Institute melanoma cell line collection.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: Amelogenin: X->X,Y.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; Wistar).
  • Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=23851445; Wistar).
  • Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45ins4aa (c.134ins12bp); Zygosity=Unspecified (PubMed=23851445).
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,02:05
HLA-BB*07:02,15:03
HLA-CC*07:02,15:05
Class II
HLA-DPDPB1*04:02,02:01:02
HLA-DQDQB1*05:01,02:01
HLA-DRDRB1*01:01,07:01
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ATCC; ESTDAB; Wistar

Markers:
AmelogeninX,Y
CSF1PO10,11
D2S133817,19
D3S135818
D5S81811
D7S82014
D8S117913,15
D13S31710,12
D16S53912
D18S5112,16
D19S43315,16
D21S1130
FGA20,22
TH018,9.3
TPOX8,11
vWA17,18

Run an STR similarity search on this cell line
Web pages https://www.wistar.org/our-scientists/meenhard-herlyn
Publications

PubMed=4053039
Herlyn M., Thurin J., Balaban G.B., Bennicelli J.L., Herlyn D., Elder D.E., Bondi E., Guerry D. IV, Nowell P.C., Clark W.H. Jr., Koprowski H.
Characteristics of cultured human melanocytes isolated from different stages of tumor progression.
Cancer Res. 45:5670-5676(1985)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

Cross-references
Cell line collections (Providers) ATCC; CRL-2811 - Discontinued
Coriell; WC00077 - Discontinued
Rockland; WM39-01-0001
Cell line databases/resources CLO; CLO_0009618
cancercelllines; CVCL_2240
ESTDAB; ESTDAB-080
Biological sample resources BioSample; SAMN03471795
Encyclopedic resources Wikidata; Q54994301
Gene expression databases GEO; GSM109041
GEO; GSM186486
GEO; GSM186487
GEO; GSM186488
GEO; GSM555136
GEO; GSM555171
Polymorphism and mutation databases Cosmic; 686399
Cosmic; 1155549
Cosmic; 1187580
Cosmic; 2159437
Cosmic; 2163807
Progenetix; CVCL_2240
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number26